Company: IMRX
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001790340-25-000135
Chunk: 429

Company: Immuneering Corp
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 8
Chunk 429
---
45,513)(110)0.2%Other income (expense)Interest income1,1782,178(1,000)(45.9)%Other income— 350 (350)(100.0)%Net loss$(44,445)$(42,985)$(1,460)3.4 %

Research and Development

The following table summarizes the components of research and development expenses for the periods indicated:

Nine Months Ended September 30,Change20252024$%(in thousands, except percentages)Direct research and development expenses by program:atebimetinib (IMM-1-104)$14,519 $12,045 $2,474 20.5 %IMM-6-4152,195 3,372 (1,177)(34.9)%Other programs4,094 4,700 (606)(12.9)%Indirect research and development expenses:Employee-related costs8,873 9,826 (953)(9.7)%Stock-based compensation expense1,946 1,960 (14)(0.7)%Facilities and other expenses985 1,020 (35)(3.4)%Depreciation/amortization182 184 (2)(1.1)%Total research and development$32,794 $33,107 $(313)(0.9)%

Research and development expenses decreased by approximately $0.3 million, or 0.9%, to approximately $32.8 million for the nine months ended September 30, 2025, as compared to approximately $33.1 million for the nine months ended September 30, 2024. The decrease of approximately $0.3 million was primarily due to a decrease of approximately $1.0 million related to indirect research and development expenses, offset by a $0.7 million increase in direct research and development expenses. Indirect expenses were driven by a $1.0 million decrease associated with employee-related costs, offset by minor increases in stock-based compensation expense, facilities and other expenses, in the aggregate. The offsetting increase in direct research and development expenses were primarily attributable to an approximately $2.5 million increase in expenses related to atebimetinib (IMM-1-104), offset by a $1.2 million decrease in expenses related to 

35

Table of Contents

IMM-6-415 driven by decreased manufacturing and preclinical spend, and by a $0.